quinoloes in the treatment of respiratory tract
TRANSCRIPT
04/11/2023 amrhamdy MD FCCP 1
QUINOLONES IN THE TREATMENT OF RESPIRATORY TRACT INFECTIONS
04/11/2023 amrhamdy MD FCCP 2
AMR BADRELDIN HAMDY
MD, FCCPPROF OF PULMONARY MEDICINE
CAIRO EGYPT
04/11/2023 amrhamdy MD FCCP 3
PULMONARY MEDICINE CONSULTANT
IBN NAFEES MEDICAL CENTRE
ABU DHABI
04/11/2023 amrhamdy MD FCCP 4
The first consideration in selecting an antimicrobial agent is whether it is indicated.
04/11/2023 amrhamdy MD FCCP 5
Antibiotics are antibacterial substances produced by various species of microorganisms (bacterial, fungi, and actinomycetes) that suppress the growth of the microorganisms.
04/11/2023 amrhamdy MD FCCP 6
Common usage often exclude the term antibiotics to include synthetic antimicrobial agents, such as sulphonamides and quinolones.
04/11/2023 amrhamdy MD FCCP 7
Antibiotics have three general uses:• Empirical therapy• Definitive therapy• Prophylactic or preventive therapy.
04/11/2023 amrhamdy MD FCCP 8
When used as empirical or initial therapy, the antibiotic should cover all the likely pathogens because the infecting organism(s) has not yet been defined.
04/11/2023 amrhamdy MD FCCP 9
Optimal and judicious selection of antimicrobial agents for the therapy of infectious diseases requires clinical judgement and detailed knowledge of pharmacological and microbiological factors.
04/11/2023 amrhamdy MD FCCP 10
The quinolones are a family of synthetic broad –spectrum antibiotic drugs.
04/11/2023 amrhamdy MD FCCP 11
The first generation of the quinolones began with the introduction of nalidixic acid in 1962 for the treatment of urinary tract infections in humans.
04/11/2023 amrhamdy MD FCCP 12
• There are simple quinolones and fluoroquinolones.• FQs are quinolone antimicrobials
having one or more fluorine substituations.
04/11/2023 amrhamdy MD FCCP 13
The ‘first generation’ FQs was introduced in 1980’s.
04/11/2023 amrhamdy MD FCCP 14
In the 1990s, compounds with additional fluoro and other substitutions have been developed (2nd generation FQs)- further extending antimicrobial activity to gram +ve cocci and anaerobes, and/ conferring metabolic stability (long t1/2), and/ or conferring metabolic stability (longer t1/2).
04/11/2023 amrhamdy MD FCCP 15
04/11/2023 amrhamdy MD FCCP 16
Therapeutic uses of simple quinolones:
• Uncomplicated urinary tract infection.• Urinary antiseptic.• Diarrhea casued by Proteus, E. coli.
Salmonella, Shigella (ampicillin resistant).
04/11/2023 amrhamdy MD FCCP 17
Fluoroquinolones are the only class of antimicrobial agents in clinical use that are direct inhibitors of bacterial DNA synthesis.
04/11/2023 amrhamdy MD FCCP 18
They inhibit two bacterial enzymes, DNA gyrase and topoisomerase IV.
04/11/2023 amrhamdy MD FCCP 19
Fluoroquinolones are bactericidal agents.
04/11/2023 amrhamdy MD FCCP 20
FQ enter the host cells and are therefore active against intracellular pathogens, e.g. Mycoplasma spp, and Chlamydia spp.
04/11/2023 amrhamdy MD FCCP 21
Spectrum of ActivityThe greatest activity of FQs is against
aerobic gm-ve bacilli, particularly Enterobacteriaceae, and against Haemophilus spp and gm-ve cocci e.g. Neisseria spp and Moraxella catarrhalis, and also against non-enteric gm-ve bacilli such as Ps aeruginosa and against staphylococci.
04/11/2023 amrhamdy MD FCCP 22
04/11/2023 amrhamdy MD FCCP 23
04/11/2023 amrhamdy MD FCCP 24
04/11/2023 amrhamdy MD FCCP 25
Use in Pregnancy
• Not used during pregnancy.• Not used in lactating mothers as it is
secreted in breast milk.
04/11/2023 amrhamdy MD FCCP 26
Use in Children
Not recommended for routine use in children less than 18 years of age (arthropathy with erosions of the cartilage in weight-bearing joints).
04/11/2023 amrhamdy MD FCCP 27
Use in Children cont’d
• Used in cystic fibrosis?• Complicated urinary tract infections
and pyelonephritis?
04/11/2023 amrhamdy MD FCCP 28
Absorption
The quinolones are well absorbed from the upper gastrointestinal tract.
04/11/2023 amrhamdy MD FCCP 29
Concentration in prostate tissue, stool, bile, lung, and neutrophlis as well as macrophages usually exceed serum concentrations.
04/11/2023 amrhamdy MD FCCP 30
Resistance
• Resistance to FQs has been slow to develop.• Increasing resistance has been
reported among Salmonella, Pseudomonas, Staphylococci, Gonococci and Pneumococci.
04/11/2023 amrhamdy MD FCCP 31
Resistance cont’d
• The likelihood of developing quinolone resistance is thought to be related to the intensity and duration of therapy.• Resistance may occur via mutations
in chromosomal genes via mutations in plasmids
04/11/2023 amrhamdy MD FCCP 32
Resistance cont’d
• The use of the most potent FQ is a logical choice if resistance has to be avoided/ delayed.• Previous exposure to an FQ in the
recent past precludes the use of a member of this class for the empirical treatment of CAP.
04/11/2023 amrhamdy MD FCCP 33
Among “atypicals’, antibiotic resistance is rare and very seldom responsible for clinical failure.
04/11/2023 amrhamdy MD FCCP 34
Side Effects
04/11/2023 amrhamdy MD FCCP 35
Gastrointestinal
• Occurs in 3-17% of patients.• Anorexia, nausea, vomiting, and
diarrhea. • Abdominal discomfort.
04/11/2023 amrhamdy MD FCCP 36
Nervous System
• In 0.9 -11%.• Mild headache and dizziness.• Insomnia.• Alteration of mood.• Hallucinations, delirium, seizures.
04/11/2023 amrhamdy MD FCCP 37
Rash and other Allergic Manifestations
• In 0.4-2.2 %.• Photo toxicity.
04/11/2023 amrhamdy MD FCCP 38
Arthropathy• Arhtropathy with cartilage erosions
and non inflammatory effusions occurs in the weight-bearing joints (in animals).• Tendinopathy and tendon ruptures
have been reported, mainly the Achilles tendon, also rotator cuff, hand, biceps, and thumb.
04/11/2023 amrhamdy MD FCCP 39
Arrhythmia and QT Interval Prolongation
Moxifloxacin, levofloxacin and gemifloxacin should be avoided in patients with known QT interval prolongation and with hypokalemia, hypomagnesemia and use of anti arrhythmic drugs.
04/11/2023 amrhamdy MD FCCP 40
Contraindications
04/11/2023 amrhamdy MD FCCP 41
• Known allergy to the drug.• Epilepsy.• QT prolongation.• Pre-existing CNS lesions or
inflammation or stroke.• With benzodiazepines
04/11/2023 amrhamdy MD FCCP 42
In the USA, a “Black Box” warning of increased risk of developing tendonitis and tendon rupture in patients of all ages. This risk is further increased in individuals over 60 yrs, taking CS drugs, and have received kidney, heart or lung transplantations.
04/11/2023 amrhamdy MD FCCP 43
May exacerbate weakness in patients with myasthenia gravis due to their neuromuscular blocking activity.
04/11/2023 amrhamdy MD FCCP 44
Combination Therapy
04/11/2023 amrhamdy MD FCCP 45
1. For empirical therapy of an infection in which the cause is unknown.
2. For treatment of polymicrobial infections.
3. To enhance antimicrobial activity( i.e. synergism) for a specific infection.
4. To prevent the emergence of resistance.
04/11/2023 amrhamdy MD FCCP 46
Uses of FQs
• Upper respiratory tract infections.• Lower respiratory tract infections.• MD resistant TB.
04/11/2023 amrhamdy MD FCCP 47
Upper Respiratory Tract Infections
04/11/2023 amrhamdy MD FCCP 48
Guidelines from the IDSA ( Infection Disease Society of America) recommend the following options for empiric-second line treatment for ABRS:
04/11/2023 amrhamdy MD FCCP 49
• Amoxicillin-clavulanate 2000mg/125 mg b.i.d.• Levofloxacin 500mg/ day.• Moxifloxacin 400mg/ day.
04/11/2023 amrhamdy MD FCCP 50
If improvement is seen within 3-5 days of initiation of therapy, a total course duration of 7-10 days is recommended.
04/11/2023 amrhamdy MD FCCP 51
Lower Respiratory Tract Infections
04/11/2023 amrhamdy MD FCCP 52
Community-aquired LRTI is a very common cause of acute illness and probably the most common reason for lost working time in adults.
04/11/2023 amrhamdy MD FCCP 53
The spectrum of disease ranges from a mild mucosal colonization or infection, an acute bronchitis or AE/COPD to an overwhelming parenchyma infection with the patient presenting with a severe CAP.
04/11/2023 amrhamdy MD FCCP 54
It is an acute illness (present for 21 days or less), usually with cough as the main symptom, with at least one other LRT symptom (sputum, dyspnea, wheeze or chest discomfort/pain) and no alternative explanation (e.g. sinusitis or asthma).
04/11/2023 amrhamdy MD FCCP 55
Definitive CAP• Is an acute illness with cough and at
least one of new focal chest signs, fever more than 4 days or dyspnea/ tachypnea, and without an obvious cause. • Supported by chest radiograph
findings of lung shadowing that is likely to be new.
04/11/2023 amrhamdy MD FCCP 56
• CAP is a common and potentially serious illness.• It is associated with considerable
morbidity and mortality, particularly in elderly patients and those with significant co-morbidities.
04/11/2023 amrhamdy MD FCCP 57
• Pneumonia, which is most often a bacterial disease, should, in general, be treated with antibiotics.• A delay of more than 8 hours in
treatment is associated with increased mortality.
04/11/2023 amrhamdy MD FCCP 58
Older quinolones, such as ciprofloxacin and ofloxacin have rather poor anti-pneumococcal efficacy and are not recommended for the empirical treatment of CAP.
04/11/2023 amrhamdy MD FCCP 59
Advantages of Respiratory FQ
• They exhibit broad spectrum coverage including all common LRTI pathogens.
• They have a high bioavailability.• They have good penetration resulting in
high intra-celullar concentrations.• A long half-life permitting once or twice
daily dosing.• Are rapidly bactericidal.
04/11/2023 amrhamdy MD FCCP 60
Respiratory quinolones are more likely to result in treatment success than the combination of a beta-lactam plus a microlide for treatment of CAP.
04/11/2023 amrhamdy MD FCCP 61
AE/COPDAn event in the natural course of the
disease characterized by a worsening of the patient’s baseline dyspnea, cough and/or sputum beyond day-to-day variability sufficient to warrant a change in management (chest radiograph shadowing consistent with infection confirms CAP)
04/11/2023 amrhamdy MD FCCP 62
The newer FQs have excellent intrinsic activity against Str. Pneumonia, H. influenzae, Moraxella catarrhalis and the atypical respiratory pathogens.
04/11/2023 amrhamdy MD FCCP 63
• FQs may be used as mono-therapy to treat high risk patients with AE/COPD, for patients with CAP requiring hospitalization, but not admission to ICU.• The newer FQs often achieve clinical
cure rates in more than 90 % of these patients.
04/11/2023 amrhamdy MD FCCP 64
Key factors to consider when selecting Antibacterial Therapy for LRTIs
04/11/2023 amrhamdy MD FCCP 65
04/11/2023 amrhamdy MD FCCP 66
04/11/2023 amrhamdy MD FCCP 67
04/11/2023 amrhamdy MD FCCP 68
04/11/2023 amrhamdy MD FCCP 69
Modifying factors that Increase the Risk of Infection with Specific Pathogens
04/11/2023 amrhamdy MD FCCP 70
04/11/2023 amrhamdy MD FCCP 71
04/11/2023 amrhamdy MD FCCP 72
04/11/2023 amrhamdy MD FCCP 73
04/11/2023 amrhamdy MD FCCP 74
04/11/2023 amrhamdy MD FCCP 75
Risk Factors for MDR Pathogens Causing HAP, HCAP, and VAP
04/11/2023 amrhamdy MD FCCP 76
Treatment of MDR TB
04/11/2023 amrhamdy MD FCCP 77
• There appears to be an increase in multidrug- resistant TB.• It was estimated that in 2004 half a
million new cases of MDR-TB cases were diagnosed world wide.
04/11/2023 amrhamdy MD FCCP 78
Of the new compounds being tested for their efficacy in TB treatment, the FQ are the first novel drugs since the development of rifamycins to have been shown to have significant activity against M. tuberculosis.
04/11/2023 amrhamdy MD FCCP 79
• Multidrug-resistant TB (MDR-TB) is defined as TB resistant to at least isoniazid and rifampin.• Extensively drug-resistant TB (XDR-
TB) is caused by MDR strains that are also resistant to at least one FQ and one or more injectable agents.
04/11/2023 amrhamdy MD FCCP 80
• The anti-TB activity of FQs has been under investigation since the 1980s.• FQs are novel anti-TB drugs to be
used when a patient is infected with a MDR-TB strain.
04/11/2023 amrhamdy MD FCCP 81
Many are active in vitro but only a few, including oflaxicin, ciprofloxacin, levofloxacin, sparfloxacin, levofloxacin and lemofloxaxin, have been clinically assessed.
04/11/2023 amrhamdy MD FCCP 82
• The choice of FQ should be based not only on the in vitro activity, but also on the long-term tolerance.• The in vivo activity of FQs is
concentration dependent.
04/11/2023 amrhamdy MD FCCP 83
• The administration of FQ for CAP patients with TB has been associated with delay in diagnosis and increased resistance and poor outcomes.• Multiple FQs prescriptions for
undiagnosed TB were more likely to have FQ resistant M. TB.
04/11/2023 amrhamdy MD FCCP 84
According to a recent meta analysis of 11 randomized controlled trials comprising a total of 1,514 patients, no statistically significant difference was observed in relation to cure, treatment failure and clinical and radiological improvement when first-line drugs were replaced by a FQ (ciprofloxacin, oflaxacin or moxifloxacin).
04/11/2023 amrhamdy MD FCCP 85
Thus, there is currently no justification for the substitution of a FQ for first line drugs or the addition of a FQ to the standard regime.
04/11/2023 amrhamdy MD FCCP 86
Moxifloxacin at the recommended daily dose of 400mg is the most active FQ against TB, while ciprofloxacin is the least effective.
04/11/2023 amrhamdy MD FCCP 87
Warning
The broad spectrum activity and common use against many other infections is also concern, since widespread use of this class of antibiotics may lead to a rapid increase in already emerging resistance problems.
04/11/2023 amrhamdy MD FCCP 88
It is wise not to use respiratory FQs as a first-line therapy for LRTI, but to reserve these drugs for selected patients with CAP.
04/11/2023 amrhamdy MD FCCP 89
04/11/2023 amrhamdy MD FCCP 90
References
04/11/2023 amrhamdy MD FCCP 91
• Andriole VT: The Quinolones. Acadamic Press (1989).
04/11/2023 amrhamdy MD FCCP 92
THANK YOU